Spots Global Cancer Trial Database for sarcomatoid
Every month we try and update this database with for sarcomatoid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma | NCT00068393 | Metastatic Rena... Renal Cell Carc... | Doxorubicin Gemcitabine G-CSF (granuloc... Neulasta | 18 Years - | Eastern Cooperative Oncology Group | |
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma | NCT00068393 | Metastatic Rena... Renal Cell Carc... | Doxorubicin Gemcitabine G-CSF (granuloc... Neulasta | 18 Years - | Eastern Cooperative Oncology Group | |
EPO906 Therapy in Patients With Advanced Kidney Cancer | NCT00035243 | Kidney Neoplasm... | epothilone b | 18 Years - 85 Years | Novartis | |
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity | NCT01024946 | Malignant Pleur... | everolimus | 18 Years - | Memorial Sloan Kettering Cancer Center | |
EPO906 Therapy in Patients With Advanced Kidney Cancer | NCT00035243 | Kidney Neoplasm... | epothilone b | 18 Years - 85 Years | Novartis |